Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News Archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1843 results
March 2017
-
Media Release
New data demonstrate Sandoz proposed biosimilar adalimumab has equivalent efficacy to reference medicine
Sandoz proposed biosimilar adalimumab (GP2017) shown to have equivalent efficacy and a similar safety profile as reference medicine, Humira®*Comprehensive development program show potential of GP2017… -
Inside a cancer diagnosis
Melanoma survivor T.J. Sharpe shares key insights about the cancer diagnosis experience.
-
In The News
World Malaria Report 2016: keeping up the momentum
Harald Nusser, Head of Novartis Social Business shares his insights from the launch of the World Malaria report 2016 in London. -
In The News
At a Juncture in Malaria Eradication
Harald Nusser, Head of Novartis Social Business reflects on the chance of reaching a malaria-free world within our generation. -
In The News
What is really driving malaria control is the personal accountability and passion of community health workers
Harald Nusser, Head of Novartis Social Business shares his insights following the latest National Malaria Control Program best practice sharing workshop in Dakar.
February 2017
-
Rare Every Day: Experiences, challenges and victories of the rare disease community
-
Media Release
Novartis Aktionäre genehmigen an der ordentlichen Generalversammlung alle Anträge des Verwaltungsrats
Aktionäre genehmigen für 2016 die 20. Dividendenerhöhung in Folge auf CHF 2,75 pro Aktie (+2%) - dies entspricht einer Rendite von 3,5% und einer Ausschüttungsquote von circa 69% des Free Cashflow… -
Media Release
Novartis shareholders approve all resolutions proposed by Board of Directors at the Annual General Meeting
Shareholders approve 20th consecutive dividend increase to CHF 2.75 (+2%) per share for 2016; representing a 3.5% yield and approximately 69% payout of free cash flow Dr. Joerg Reinhardt… -
Media Release
Les actionnaires de Novartis approuvent toutes les résolutions proposées par le Conseil d'administration lors de l'Assemblée générale annuelle
Les actionnaires approuvent la 20e hausse consécutive du dividende, à CHF 2,75 (+2 %) par action au titre de l'exercice 2016. Cela représente un rendement de 3,5 % et une distribution du free cash-… -
Media Release
Novartis receives positive CHMP opinion for Tafinlar® + Mekinist® in BRAF-positive non-small cell lung cancer (NSCLC) patients
If approved, Tafinlar + Mekinist will be the first targeted therapy specifically for NSCLC patients with a BRAF V600 mutation CHMP opinion based on positive data from pivotal study of patients… -
Meet T.J. Sharpe
Meet Melanoma survivor TJ Sharpe in the first installment of his new blog series on Novartis.com.
-
In The News
Novartis Access perspectives: Pharma partners with African countries on chronic diseases
In an editorial for Pharmaphorum, Dr. Kiliko, Head Customer Services at Mission for Essential Drugs and Supplies (MEDS), showcases how Pharma companies play a vital role in improving access-to-…
Pagination
- ‹ Previous page
- 1
- …
- 114
- 115
- 116
- 117
- 118
- 119
- 120
- …
- 154
- › Next page
Test disclaimer...!!!